Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry

Monday, July 14, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

SHANGHAI, China, July 14 WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology and medical device research anddevelopment outsourcing company with operations in China and the UnitedStates, announced today that Dr. Richard M. Soll has joined WuXi PharmaTech asVice President of Medicinal Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

As a pharmaceutical veteran, Dr. Soll brings over 25 years of scientificexperience and proven leadership capability to his new role in WuXi. Prior tojoining WuXi, Dr. Soll worked at TargeGen Inc., a San Diego basedbiotechnology company, as Vice President of Research and Development and ChiefScientific Officer from March 2003 to March 2008. Before joining TargeGen,Dr. Soll held senior positions with increasing responsibilities at OntogenCorporation and 3-Dimensional Pharmaceutical, Inc.

Dr. Soll is well recognized and respected for his scientific acuity fromthe academic and industry circles. Amongst his most recent achievements arefirst-in-class drug development nomination candidates and clinical developmentdrugs for potential treatment for cancer, thrombosis, ocular disease,inflammation, edema and myeloproliferative disorders.

As the Vice President of Medicinal Chemistry Dr. Soll will help thecompany to expand and strengthen its medicinal chemistry services platform.Dr. Soll will report directly to Dr. Shuhui Chen, Chief Scientific Officer ofWuXi PharmaTech.

"I am very excited to welcome Dr. Soll on board to lead and expand ouralready strong medicinal chemistry unit," commented Dr. Ge Li, Chairman andChief Executive Officer of WuXi PharmaTech. "Previously a customer of WuXi,Rich has a unique perspective on how to maximize service value creation forclients. His broad experience in the pharmaceutical industry and proven trackrecord as a leader make him an ideal fit for the organization. I am confidentthat under his leadership our medicinal chemistry service capability will bestronger and further integrated with those of other services."

Dr. Soll received his B.S. in Chemistry from the University ofMassachusetts, Massachusetts and his Ph.D. in Chemistry from DartmouthCollege, New Hampshire. He was also a chemistry post-doctoral fellow atHarvard University with Professor E. J. Corey.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the UnitedStates. As a research-driven and customer-focused company, WuXi PharmaTechprovides pharmaceutical, biotechnology and medical device companies a broadand integrated portfolio of laboratory and manufacturing services throughoutthe drug and medical device R&D process. WuXi PharmaTech's services aredesigned to assist its global partners in shortening the cycle and loweringthe cost of drug and medical device R&D. For more information, please visit:http://www.wuxipharmatech.com .For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: pr@pharmatechs.com

SOURCE WuXi PharmaTech (Cayman) Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store